Huvepharma® invests in solar energy

Huvepharma® has started the process of decarbonising its production facilities by relying on its own energy production from renewable sources. Additionally, to address indirect emissions (scope 3), the company commits to engage partners upstream and downstream the value chain. All of these actions are part of a longer-term vision to achieve carbon-neutral production. Huvepharma® is Environment, Social and Governance (ESG) driven and, to achieve the commitments made, establishing good practices are part of the business strategy, following a rigorous implementation plan. The company already operates a solar plant with a capacity of 25MW and will increase its capacity to 200 MW by the end of 2023 and 300 MW by 2030. This is the equivalent of the energy supply for 300,000 households. Huvepharma® will be certified as carbon neutral as a result of its installed capacity of solar energy. You can read more about Huvepharma®’s sustainability projects on HuGo (search ‘Sustainability’).

Global Quality News

Huvepharma® continues to place the highest emphasis on our Quality standards. In 2022, Huvepharma® passed a number of inspections and audits. In summary:

• Huvepharma®’s largest manufacturing site in Bulgaria successfully passed the US FDA inspection
• Huvepharma®’s manufacturing sites and affiliates worldwide passed numerous inspections by local, national and international regulatory bodies and audits by our customers.
• Superior Quality Management
• Food Safety
• Health & Environmental Safety
• Information Security
• ISO 9001/ 14001/ 27001/ 45001

Huvepharma retains its certifications for:

• Feed Chain Alliance
• FSCC 22000
• Kosher
• Halal

Huvepharma® is a global pioneer in the production and distribution of Organic Feed Additives and has retained its Organic certification.

New production facility

In June 2021 the new production line for Albiotic® started to operate in Biovet® Peshtera. Its capacity is 5000 syringes per hour. There is a 24-hours production opportunity which means that we can produce 100 000 syringes daily. Albiotic ®330 mg/100 mg intramammary solution is a sterile aqueous antibiotic solution for intramammary administration in lactating cows for the treatment of mastitis. The composition of the product includes the combination of two antibiotics - Lincomycin and Neomycin, dissolved in water for injections together with excipients. Each syringe (10 ml) contains 33 mg/ml Lincomycin hydrochloride and 10 mg/ml Neomycin sulphate.